Acute Myeloid Leukemia Highlights from ASCO & EHA 2023

Virtual webinar featuring presentations & discussions on selected abstracts

Chaired by Naval Daver
Moderators: Jessica Altman, Daniel Pollyea and Courtney DiNardo

20 June, 09:00-11:00 EST / 14:00-16:00 BST / 15:00-17:00 CET

Apply for registration here

Agenda:

9.00 – 9.05
Introduction  

9:05 – 9:40
Newly Diagnosed AML

Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.
Jorge Cortes – ASCO 7027

Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia.
Joshua Mitchell – ASCO 7029

Real-world effectiveness and safety of cpx-351 in patients aged <60 and ≥60 years with newly diagnosed acute myeloid leukemia: crest-UK post-hoc analysis
Priyanka Mehta – EHA 486

Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts) ≥ 60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus Venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML).
Jayastu Senapati – ASCO 7047

Panel discussion

09:40 – 10:10
FLT3

Azacitidine, Venetoclax and Gilteritinib for patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A subgroup analysis from a Phase II Study
Nicholas Short – EHA P485

Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus Quizartinib versus placebo in adult patients with newly diagnosed flt3-itd wild-type AML
Pau Montesinos – EHA S130

BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor Gilteritinib as post-transplant maintenance for FLT3-ITD AML
Mark Levis – EHA PF251

Panel discussion

10:10 – 10:35
Venetoclax-based regimens

Addition of Venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian Cooperative analysis.
Alfonso Piciocchi – ASCO Abstract 7013

Long-Term Outcomes of Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax + HMA Therapies
Keith Pratz – EHA P525

Panel discussion

10:35 – 11:35
IO/Novel/Early Phase

A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
Anthony Stein – ASCO 7005

A Phase I/II study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in combination with Standard of care in patients with Myeloid malignancies (Bexmab) –
Mika Kontro – EHA P542

Interim Analysis of a Registration Enabling Study of Pivekimab Sunirine (PVEK, IMGN632) A CD123-targeting antibody-drug conjugate, in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDC)
Naveen Pemmaraju – EHA S139

Activity, tolerability, and resistance profile of the Menin inhibitor Ziftomenib in adults with relapsed/refractory NPM1-mutated AML
Amir Fathi – EHA LB2713

Olutasidenib in post-Venetoclax Patients with mutant LDH1 AML
Jorge Cortes – EHA P555

Panel discussion

11:35-11:40
Conclusions and meeting close

Please note that registration is open to healthcare professionals only and registration is subject to approval.
Your application will be reviewed and confirmed by email.

The Post-ASCO & EHA 2023 AML Highlights webinar has been supported by:

Gold Supporters